Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2002

View Archived Issues

Novel calcium receptor modulators and their use described in Aventis patent

Two Shionogi patents describe novel immunosuppressant agents

Merck reports development of inhibitors of p38 kinase

Novel cytokine and T-cell production inhibitors and their use in cancer, arthritis, etc.

KN-62 inhibits MAPK/c-Myc activation and proliferation in human keratinocytes

NO-1886 combined with exercise may prevent development of atherosclerosis in the elderly

The antifungal clotrimazole exhibits neuroprotective effects in vitro

PARP inhibitor GPI-6150 effective in rat model of colitis

Antiamnesic effects of DM-232 demonstrated in mice and rats

Efficacy of IS-741 on spontaneous colitis in transgenic rat model

New inhibitors of malonyl-CoA decarboxylase and their use in heart failure, diabetes, obesity, etc.

Vical updates progress of Leuvectin program

Enrollment completed in DIAMOND and SILVER ALT-711 trials

Extended-spectrum oxazolidinone selected for clinical development

INS-37217, a next-generation P2Y2 agonist with an enhanced duration of action

Phase III data in immunocompromised patient population presented for micafungin

Positive results emerge from pilot trial of SCV-07 in tuberculosis

Polyphenon enters pivotal phase III trial for genital warts

Idec gains license to develop HMN-214

IND cleared for Alzhemed phase II

Orphan drug grant for Endostatin trial

Clinical efficacy and safety of ACH-126443 in HBV demonstrated in phase I/II clinical trial

InterMune and Array BioPharma collaborate on hepatitis drug discovery

Twelve-month data show efficacy of anecortave acetate in wet AMD

Iseganan fails to meet primary endpoint in ulcerative oral mucositis phase III trial

deCODE and Merck & Co. form obesity alliance

Triangle's Coviracil outperforms Zerit in phase III trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...